Glenmark Pharmaceuticals aims to grow revenues by 10-11% in FY24

11 Sep 2023 Evaluate

Glenmark Pharmaceuticals is aiming to grow its revenues by 10-11 per cent with a focus on free cash generation to reduce debt in the current financial year (FY24). The company is also looking at enhancing EBITDA margins while expanding presence in various therapeutic segments like oncology and dermatology. The company will identify potential candidates for development purposes on a global scale as the drug maker moves up the value chain.

Glenmark Pharmaceuticals is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in over 50 countries.


Glenmark Pharma Share Price

1040.45 -13.55 (-1.29%)
06-May-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1529.55
Dr. Reddys Lab 6315.00
Cipla 1423.40
Zydus Lifesciences 1021.00
Lupin 1679.75
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.